On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

SCOTTSDALE, Ariz. — June 16, 2025 — The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those ...

The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the ...

MYASTHENIA gravis has frequently been described as a ... including all kinds of housework. The mechanism of this particular reaction is not known. Exophthalmos due to enlargement of the eye ...

The current myasthenia gravis therapeutics market mainly consists ... J&J sees broader potential for IMAAVY beyond gMG, believing its mechanism of action could apply across multiple autoimmune ...

Myasthenia gravis (MG) is a rare ... However, its underlying mechanisms remained unclear. Now, researchers from Changchun University of Chinese Medicine have conducted a preclinical study that ...

The FDA has approved the J&J drug, known in development as nipocalimab, as a treatment for generalized myasthenia gravis (gMG ... a cell’s a built-in mechanisms for managing proteins, including ...

FcRn blockers are the leading candidates and treatments available for people with MuSK+ myasthenia gravis. However, ongoing research is exploring other mechanisms to treat this version of the disease.